Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
2.830
-0.220 (-7.21%)
At close: Jul 19, 2024, 4:00 PM
2.850
+0.020 (0.71%)
Pre-market: Jul 22, 2024, 9:02 AM EDT
Allogene Therapeutics Employees
As of December 31, 2023, Allogene Therapeutics had 233 total employees, including 232 full-time and 1 part-time employees. The number of employees decreased by 128 or -35.46% compared to the previous year.
Employees
233
Change (1Y)
-128
Growth (1Y)
-35.46%
Revenue / Employee
$279
Profits / Employee
-$1,259,918
Market Cap
590.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
ZimVie | 2,600 |
Varex Imaging | 2,400 |
Emergent BioSolutions | 1,600 |
Adaptive Biotechnologies | 709 |
Surmodics | 376 |
Verve Therapeutics | 255 |
Annexon | 71 |
Larimar Therapeutics | 42 |
ALLO News
- 21 days ago - Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Announces Q2 Investor Conference Participation - GlobeNewsWire